Chugai Pharma Manufacturing Co., Ltd. (中外製薬工業株式会社), a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., specializes in the manufacturing of pharmaceutical products, including active pharmaceutical ingredients (APIs) for small and mid-sized molecules, macrocyclic peptides, biopharmaceuticals, and high-potency solid formulations.
Headquartered in Tokyo, the company operates plants in Ukima (Tokyo), Fujieda (Shizuoka), and Utsunomiya (Tochigi). Its Fujieda Plant features advanced facilities like FJ3 for late-stage development and early commercial production of small molecules and macrocyclic peptides, supporting dual manufacturing capabilities with high containment (≤0.03 µg/m³), automation, and environmental safeguards. Previous buildings FJ1 and FJ2 enable integrated in-house supply from early clinical to commercial stages.
Recognized for innovation, its facilities have received multiple ISPE Facility of the Year Awards, including FJ3's 2026 Honorable Mention, FJ2's 2023 Innovation award, and UK4's 2024 Social Impact award.
Also known as 中外製薬工業 and CPMC.
Facility enables dual production of macrocyclic‑peptide and small‑molecule APIs with advanced automation, parallel lines, 0.03 µg/m3 containment and global-scale supply.
